Persister control by leveraging dormancy associated reduction of antibiotic efflux

Patent metadata

Field	Value
Publication number	US-2025034614-A1
Application number	US-202218710390-A
Country	US
Kind code	A1
Filing date	Nov 15, 2022
Priority date	Nov 15, 2021
Publication date	Jan 30, 2025
Grant date	—

Abstract

A strategy for bacterial persister control using amphiphilic antibiotics that do not require active transport to penetrate bacterial membranes of persister cells. Persister cells have reduced drug efflux and accumulate more minocycline than normal cells, leading to effective killing of this dormant subpopulation upon wake-up. While dormancy is a well-known cause of antibiotic tolerance, it also provides an Achilles' heel for controlling persister cells by leveraging dormancy associated reduction of drug efflux.

First claim

What is claimed is:

1 . A method of treating a bacterial infection, comprising the steps of:
administering an antibiotic to a population of bacterial cells including at least some persister cells that are tolerant to antibiotic treatment, wherein the antibiotic is capable of energy-independent diffusion such that the antibiotic does not require active transport to penetrate a membrane of each bacterial cell in the population of bacterial cells; and waking up the bacterial persister cells in the population of bacterial persister cells after the amphiphilic antibiotic is administered.

2 . The method of claim 1 , wherein the antibiotic is amphiphilic.

3 . The method of claim 1 , wherein the antibiotic is selected from the group consisting of minocycline, eravacycline, and rifamycin.

4 . The method of claim 1 , wherein the step of waking up the bacterial persister cells comprises adding an amount of nutrients to the population of bacterial cells.

5 . The method of claim 2 , wherein the step of waking up the bacterial persister cells comprises removing any extracellular antibiotics from the population of bacterial cells.

6 . The method of claim 1 , further comprising the step of administering a second antibiotic, wherein the second antibiotic is able to kill active bacterial cells.

7 . The method of claim 6 , wherein the step of administering the antibiotic capable of energy-independent diffusion and the second antibiotic requires active transport.

8 . The method of claim 6 , wherein the two antibiotics are administered at the same time.

9 . The method of claim 6 , wherein the two antibiotics are administered sequentially with the second antibiotic administered second.

10 . A method of screening compounds for efficacy against bacterial persister cells, comprising the steps of:
administering a target compound to a population of persister cells that are resistant to antibiotic treatment; waking up the bacterial persister cells in the population of bacterial persister cells after the amphiphilic antibiotic is administered; and observing whether any of the bacterial persister cells are killed after the step of waking up the bacterial persister cells.

11 . The method of claim 10 , where the step of waking up the bacterial persister cells comprises adding an amount of nutrients to the population of bacterial cells.

12 . The method of claim 11 , wherein the amount of nutrients comprises a lysogeny broth (LB).

13 . The method of claim 12 , further comprising the step of selecting the target compound from a library of compounds using physiochemical parameters matching to an antibiotic that is capable of energy-independent diffusion such that the antibiotic does not require active transport to penetrate a membrane of a bacterial cell.

14 . The method of claim 13 , where the step of selecting the target compound from the library of compounds using physiochemical parameters matching includes using a chemoinformatic clustering algorithm.

15 . The method of claim 14 , where the chemoinformatic clustering algorithm is K-means clustering.

Assignees

• Ren Dacheng
• Roy Sweta
• Univ Syracuse

Inventors

• Ren Dacheng
• Roy Sweta

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/65

  Tetracyclines · CPC title

• A61K31/343

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C12Q1/18 Primary

  Testing for antimicrobial activity of a material · CPC title